Lung Cancers Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03058289A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6Treatment
NCT02393248Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Treatment
NCT03233724The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung CancerTreatment
NCT02638090Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)Treatment
NCT02903914Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsTreatment
NCT02444741Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung CancerTreatment
NCT02407171Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLCTreatment